Dypeptidylpeptidase-4 inhibitors and the cardiovascular system: How to manage the fil rouge.

Published on Jan 3, 2019in Nutrition Metabolism and Cardiovascular Diseases3.7
· DOI :10.1016/J.NUMECD.2018.12.009
Ilaria Dicembrini26
Estimated H-index: 26
(UniFI: University of Florence),
Matteo Monami57
Estimated H-index: 57
(UniFI: University of Florence),
Edoardo Mannucci98
Estimated H-index: 98
(UniFI: University of Florence)
Source
Abstract
Abstract Dypeptidylpeptidase-4 (DPP-4) inhibitors are a therapeutic option for improving glucose control in patients with type 2 diabetes. They can be prescribed at different stages of the natural history of the disease because of their low risk for hypoglycemia and associated weight gain. For all new drugs for diabetes, the US Food and Drug Administration requires the demonstration of the cardiovascular (CV) safety profile through pooled analyses of phase 3 studies or specifically designed trials. A significant superiority over placebo has been observed with a sodium-dependent glucose transporter-2 inhibitor, empagliflozin, and two glucagon-like peptide-1 receptor agonists, liraglutide and semaglutide, thus suggesting cardioprotective effects for some antidiabetic drugs. The neutral results of CV safety trials on DPP-4 inhibitors have been disappointing, appearing to contradict the data from pooled analyses and meta-analyses of early trials. The main aim of this review is to find a possible interpretation for the differences between the results of these early trials and the CV safety studies with DPP-4 inhibitors. We conclude that the hypothesis of additional beneficial effects by DPP-4 inhibitors (beyond the improvement of glucose control), on the CV system in low-risk patients in primary prevention, needs to be verified with specifically designed studies.
📖 Papers frequently viewed together
38 Citations
9 Citations
14 Citations
References33
Newest
#1Julio Rosenstock (UTSW: University of Texas Southwestern Medical Center)H-Index: 100
#2Vlado Perkovic (UNSW: University of New South Wales)H-Index: 93
Last. Darren K. McGuireH-Index: 91
view all 19 authors...
Importance Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease. Objective To evaluate the effect of linagliptin, a selective DPP-4 inhibitor, on CV outcomes and kidney outcomes in patients with type 2 diabetes at high risk of CV and kidney events. Design, Setting, and Participants Randomized, placebo-...
487 CitationsSource
#1Mikhail Kosiborod (UMKC: University of Missouri–Kansas City)H-Index: 64
#2Carolyn S.P. Lam (NUS: National University of Singapore)H-Index: 78
Last. Cvd-Real InvestigatorsH-Index: 1
view all 13 authors...
Abstract Background Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) at high CV risk. Prior real-world data suggested similar SGLT-2i effects in T2D patients with a broader risk profile, but these studies focused on heart failure and death and were limited to the United States and Europe. Objectives The purpose of this study was to examine a broad range of CV outcomes in patie...
238 CitationsSource
#1Frederik PerssonH-Index: 34
#2Thomas Nyström (KI: Karolinska Institutet)H-Index: 30
Last. Kåre I. Birkeland (University of Oslo)H-Index: 57
view all 12 authors...
Aims To compare the sodium-glucose-cotransporter-2 (SGLT-2) inhibitor dapagliflozin with dipeptidyl peptidase-4 (DPP-4) inhibitors with regard to risk associations with major adverse cardiovascular ...
116 CitationsSource
#1Samy Suissa (JGH: Jewish General Hospital)H-Index: 108
Two recent observational studies reported a remarkably lower rate of all-cause death associated with sodium–glucose cotransporter 2 inhibitor (­SGLT2i) use in all patients with type 2 diabetes and not only those at increased cardiovascular risk. The >50% lower mortality rates reported in these studies are much greater than those found in the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) and CANagliflozin cardioVascular Assessm...
70 CitationsSource
#1Kenneth W. Mahaffey (Stanford University)H-Index: 113
#2Bruce Neal (UNSW: University of New South Wales)H-Index: 116
Last. David R. Matthews (University of Oxford)H-Index: 84
view all 12 authors...
BACKGROUND : Canagliflozin is a sodium glucose cotransporter 2 inhibitor that significantly reduces the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and elevated cardiovascular risk. The comparative effects among participants with and without a history of cardiovascular disease (secondary versus primary prevention) were prespecified for evaluation. METHODS : The CANVAS Program (Canagliflozin Cardiovascular Assessm...
253 CitationsSource
#1Edoardo Mannucci (UniFI: University of Florence)H-Index: 98
#2Ele FerranniniH-Index: 110
6 CitationsSource
#1Mei-Tzu WangH-Index: 2
#2Lin Sheng-CheH-Index: 1
Last. Wei-Chun HuangH-Index: 8
view all 10 authors...
Background Previous studies regarding the cardioprotective effects of dipeptidyl peptidase 4 (DPP-4) inhibitors have not provided sufficient evidence of a relationship between DPP-4 inhibition and actual cardiovascular outcomes. This study aimed to evaluate the impact of DPP-4 inhibitors on the survival of diabetic patients after first acute myocardial infarction (AMI).
25 CitationsSource
#1Mikhail Kosiborod (UMKC: University of Missouri–Kansas City)H-Index: 64
#2Matthew A. Cavender (UNC: University of North Carolina at Chapel Hill)H-Index: 25
Last. Peter Fenici (AstraZeneca)H-Index: 17
view all 14 authors...
Background: Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recently reported with the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) empagliflozin in patients with type 2 diabetes mellitus who have atherosclerotic cardiovascular disease. We compared HHF and death in patients newly initiated on any SGLT-2i versus other glucose-lowering drugs in 6 countries to determine if these benefits are seen in real-world practice and across SGLT-2i class. Methods: Data ...
477 CitationsSource
#1Edoardo Mannucci (UniFI: University of Florence)H-Index: 98
#2Matteo Monami (UniFI: University of Florence)H-Index: 57
Last. Carlo Maria Rotella (UniFI: University of Florence)H-Index: 58
view all 4 authors...
4 CitationsSource
#1Steven P. Marso (Research Medical Center)H-Index: 61
#2Stephen C. Bain (Swansea University)H-Index: 53
Last. Jonas Pettersson (Novo Nordisk)H-Index: 17
view all 15 authors...
BackgroundRegulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular risk. The cardiovascular effects of semaglutide, a glucagon-like peptide 1 analogue with an extended half-life of approximately 1 week, in type 2 diabetes are unknown. MethodsWe randomly assigned 3297 patients with type 2 diabetes who were on a standard-care regimen to receive once-weekly semaglutide (0.5 mg or 1...
2,341 CitationsSource
Cited By1
Newest
#1Mitsuhiro Kawakubo (Nagoya University)H-Index: 1
#2Miyako Tanaka (Nagoya University)H-Index: 21
Last. Takayoshi Suganami (Nagoya University)H-Index: 54
view all 20 authors...
Nonalcoholic steatohepatitis (NASH) is a hepatic phenotype of the metabolic syndrome, and increases the risk of cirrhosis and hepatocellular carcinoma (HCC). Although increasing evidence points to the therapeutic implications of certain types of anti-diabetic agents in NASH, it remains to be elucidated whether their effects on NASH are independent of their effects on diabetes. Genetically obese melanocortin 4 receptor–deficient (MC4R-KO) mice fed Western diet are a murine model that sequentially...
16 CitationsSource